Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the Intergroup Rhabdomyosarcoma Study Group

P. P. Breitfeld, E. Lyden, R. B. Raney, L. A. Teot, M. Wharam, T. Lobe, W. M. Crist, H. M. Maurer, S. S. Donaldson, F. B. Ruymann

Research output: Contribution to journalArticle

Abstract

Purpose: This study was designed to estimate the partial and complete response rates (CR and PR) of two novel drug pairs (vincristine and melphalan vs. ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma. Patients and Methods: One hundred twenty-eight patients were randomly assigned to phase II window therapy consisting of vincristine and melphalan (VM-containing regimen) or ifosfamide and etoposide (IE-containing regimen). Brief window therapy (12 wks) was immediately followed-up by vincristine, dactinomycin, and cyclophosphamide (VAC), chemotherapy, surgery, and irradiation, with continuation of either VM or IE in patients with initial response. Major endpoints were initial CR and PR rates after the phase II window phase of therapy, failure-free survival (FFS), and survival. Results: Patients who received the VM-containing regimen experienced significantly more anemia, neutropenia, thrombocytopenia, and had more cyclophosphamide dose reductions. The initial PR and CR rates were not significantly different for patients treated with either regimen (VM, 74%; IE, 79%; P = 0.428). However, FFS and overall survival (OS) at 3 years were significantly better with the IE-containing regimen (FFS: 33% vs. 19%; P = 0.043; OS: 55% vs. 27%; P = 0.012). Conclusions: Although the VM-containing regimen produced a high response rate, inclusion of melphalan appeared to limit the cyclophosphamide dose that could be administered, and ultimately, this regimen was associated with a significantly worse outcome than was the IE-containing regimen. Also, the IE-containing regimen was associated with a gratifyingly high survival rate at 3 years (55%), which is significantly higher than has been observed on any previous Intergroup Rhabdomyosarcoma Study Group regimen for similar patients. We believe that this promising outcome indicates that this drug pair merits further randomized testing in metastatic rhabdomyosarcoma.

Original languageEnglish (US)
Pages (from-to)225-233
Number of pages9
JournalJournal of Pediatric Hematology/Oncology
Volume23
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Ifosfamide
Melphalan
Rhabdomyosarcoma
Vincristine
Etoposide
Combination Drug Therapy
Pediatrics
Survival
Cyclophosphamide
Dactinomycin
Neutropenia
Thrombocytopenia
Pharmaceutical Preparations
Anemia
Therapeutics
Survival Rate
Drug Therapy

Keywords

  • Chemotherapy
  • Children
  • Etoposide
  • Ifosfamide
  • Melphalan
  • Metastatic
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy : A report from the Intergroup Rhabdomyosarcoma Study Group. / Breitfeld, P. P.; Lyden, E.; Raney, R. B.; Teot, L. A.; Wharam, M.; Lobe, T.; Crist, W. M.; Maurer, H. M.; Donaldson, S. S.; Ruymann, F. B.

In: Journal of Pediatric Hematology/Oncology, Vol. 23, No. 4, 2001, p. 225-233.

Research output: Contribution to journalArticle

Breitfeld, P. P. ; Lyden, E. ; Raney, R. B. ; Teot, L. A. ; Wharam, M. ; Lobe, T. ; Crist, W. M. ; Maurer, H. M. ; Donaldson, S. S. ; Ruymann, F. B. / Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy : A report from the Intergroup Rhabdomyosarcoma Study Group. In: Journal of Pediatric Hematology/Oncology. 2001 ; Vol. 23, No. 4. pp. 225-233.
@article{9d2b080b1dce48d09450bfbc0815021d,
title = "Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the Intergroup Rhabdomyosarcoma Study Group",
abstract = "Purpose: This study was designed to estimate the partial and complete response rates (CR and PR) of two novel drug pairs (vincristine and melphalan vs. ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma. Patients and Methods: One hundred twenty-eight patients were randomly assigned to phase II window therapy consisting of vincristine and melphalan (VM-containing regimen) or ifosfamide and etoposide (IE-containing regimen). Brief window therapy (12 wks) was immediately followed-up by vincristine, dactinomycin, and cyclophosphamide (VAC), chemotherapy, surgery, and irradiation, with continuation of either VM or IE in patients with initial response. Major endpoints were initial CR and PR rates after the phase II window phase of therapy, failure-free survival (FFS), and survival. Results: Patients who received the VM-containing regimen experienced significantly more anemia, neutropenia, thrombocytopenia, and had more cyclophosphamide dose reductions. The initial PR and CR rates were not significantly different for patients treated with either regimen (VM, 74{\%}; IE, 79{\%}; P = 0.428). However, FFS and overall survival (OS) at 3 years were significantly better with the IE-containing regimen (FFS: 33{\%} vs. 19{\%}; P = 0.043; OS: 55{\%} vs. 27{\%}; P = 0.012). Conclusions: Although the VM-containing regimen produced a high response rate, inclusion of melphalan appeared to limit the cyclophosphamide dose that could be administered, and ultimately, this regimen was associated with a significantly worse outcome than was the IE-containing regimen. Also, the IE-containing regimen was associated with a gratifyingly high survival rate at 3 years (55{\%}), which is significantly higher than has been observed on any previous Intergroup Rhabdomyosarcoma Study Group regimen for similar patients. We believe that this promising outcome indicates that this drug pair merits further randomized testing in metastatic rhabdomyosarcoma.",
keywords = "Chemotherapy, Children, Etoposide, Ifosfamide, Melphalan, Metastatic, Rhabdomyosarcoma",
author = "Breitfeld, {P. P.} and E. Lyden and Raney, {R. B.} and Teot, {L. A.} and M. Wharam and T. Lobe and Crist, {W. M.} and Maurer, {H. M.} and Donaldson, {S. S.} and Ruymann, {F. B.}",
year = "2001",
doi = "10.1097/00043426-200105000-00010",
language = "English (US)",
volume = "23",
pages = "225--233",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy

T2 - A report from the Intergroup Rhabdomyosarcoma Study Group

AU - Breitfeld, P. P.

AU - Lyden, E.

AU - Raney, R. B.

AU - Teot, L. A.

AU - Wharam, M.

AU - Lobe, T.

AU - Crist, W. M.

AU - Maurer, H. M.

AU - Donaldson, S. S.

AU - Ruymann, F. B.

PY - 2001

Y1 - 2001

N2 - Purpose: This study was designed to estimate the partial and complete response rates (CR and PR) of two novel drug pairs (vincristine and melphalan vs. ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma. Patients and Methods: One hundred twenty-eight patients were randomly assigned to phase II window therapy consisting of vincristine and melphalan (VM-containing regimen) or ifosfamide and etoposide (IE-containing regimen). Brief window therapy (12 wks) was immediately followed-up by vincristine, dactinomycin, and cyclophosphamide (VAC), chemotherapy, surgery, and irradiation, with continuation of either VM or IE in patients with initial response. Major endpoints were initial CR and PR rates after the phase II window phase of therapy, failure-free survival (FFS), and survival. Results: Patients who received the VM-containing regimen experienced significantly more anemia, neutropenia, thrombocytopenia, and had more cyclophosphamide dose reductions. The initial PR and CR rates were not significantly different for patients treated with either regimen (VM, 74%; IE, 79%; P = 0.428). However, FFS and overall survival (OS) at 3 years were significantly better with the IE-containing regimen (FFS: 33% vs. 19%; P = 0.043; OS: 55% vs. 27%; P = 0.012). Conclusions: Although the VM-containing regimen produced a high response rate, inclusion of melphalan appeared to limit the cyclophosphamide dose that could be administered, and ultimately, this regimen was associated with a significantly worse outcome than was the IE-containing regimen. Also, the IE-containing regimen was associated with a gratifyingly high survival rate at 3 years (55%), which is significantly higher than has been observed on any previous Intergroup Rhabdomyosarcoma Study Group regimen for similar patients. We believe that this promising outcome indicates that this drug pair merits further randomized testing in metastatic rhabdomyosarcoma.

AB - Purpose: This study was designed to estimate the partial and complete response rates (CR and PR) of two novel drug pairs (vincristine and melphalan vs. ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma. Patients and Methods: One hundred twenty-eight patients were randomly assigned to phase II window therapy consisting of vincristine and melphalan (VM-containing regimen) or ifosfamide and etoposide (IE-containing regimen). Brief window therapy (12 wks) was immediately followed-up by vincristine, dactinomycin, and cyclophosphamide (VAC), chemotherapy, surgery, and irradiation, with continuation of either VM or IE in patients with initial response. Major endpoints were initial CR and PR rates after the phase II window phase of therapy, failure-free survival (FFS), and survival. Results: Patients who received the VM-containing regimen experienced significantly more anemia, neutropenia, thrombocytopenia, and had more cyclophosphamide dose reductions. The initial PR and CR rates were not significantly different for patients treated with either regimen (VM, 74%; IE, 79%; P = 0.428). However, FFS and overall survival (OS) at 3 years were significantly better with the IE-containing regimen (FFS: 33% vs. 19%; P = 0.043; OS: 55% vs. 27%; P = 0.012). Conclusions: Although the VM-containing regimen produced a high response rate, inclusion of melphalan appeared to limit the cyclophosphamide dose that could be administered, and ultimately, this regimen was associated with a significantly worse outcome than was the IE-containing regimen. Also, the IE-containing regimen was associated with a gratifyingly high survival rate at 3 years (55%), which is significantly higher than has been observed on any previous Intergroup Rhabdomyosarcoma Study Group regimen for similar patients. We believe that this promising outcome indicates that this drug pair merits further randomized testing in metastatic rhabdomyosarcoma.

KW - Chemotherapy

KW - Children

KW - Etoposide

KW - Ifosfamide

KW - Melphalan

KW - Metastatic

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0034994886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034994886&partnerID=8YFLogxK

U2 - 10.1097/00043426-200105000-00010

DO - 10.1097/00043426-200105000-00010

M3 - Article

C2 - 11846301

AN - SCOPUS:0034994886

VL - 23

SP - 225

EP - 233

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -